Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 13;20(1):213.
doi: 10.1186/s12967-022-03420-9.

Recommendations for addressing the translational gap between experimental and clinical research on amyloid diseases

Miriam Solomon  1 , Vito Foderà  2 , Annette Eva Langkilde  3 , Perry Elliott  4 , Fabrizio Tagliavini  5 , Trevor Forsyth  6   7 , Oxana Klementieva  8   9 , Vittorio Bellotti  10   11
Affiliations

Recommendations for addressing the translational gap between experimental and clinical research on amyloid diseases

Miriam Solomon et al. J Transl Med. .

Abstract

This paper is a report of recommendations for addressing translational challenges in amyloid disease research. They were developed during and following an international online workshop organized by the LINXS Institute of Advanced Neutron and X-Ray Science in March 2021. Key suggestions include improving cross-cultural communication between basic science and clinical research, increasing the influence of scientific societies and journals (vis-à-vis funding agencies and pharmaceutical companies), improving the dissemination of negative results, and strengthening the ethos of science.

Keywords: Alzheimer’s disease; Amyloid diseases; Complexity; Heterogeneity; Negative results; Translational medicine.

PubMed Disclaimer

Conflict of interest statement

PE reports consulting for Pfizer, Astra Zeneca and NovoNordisk. OK, TF, MS, VF, VB, AL declare that they have no known competing financial interests or personal relationships that have influenced the work reported in this paper. All authors report that the funders had no role in the in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.

Figures

Fig. 1
Fig. 1
Schematic representation of the expertise workshop participates. A The coloured area A represents amyloid diseases. B Disease relevant expertise of clinical scientists. C Clinical expertise in other areas D Basic scientists whose major research interest is in amyloid disease E Basic scientists in other research areas F Overlap of clinical and basic research expertise in the area of amyloid diseases
Fig. 2
Fig. 2
Major obstacles and influence of scientific strategies in amyloid diseases
Fig. 3
Fig. 3
Publishing negative results
Fig. 4
Fig. 4
Driving force in clinical and basic science in amyloid diseases
See this image and copyright information in PMC

References

    1. Perutz MF. Mutations make enzyme polymerize. Nature. 1997;385:773–775. doi: 10.1038/385773a0. - DOI - PubMed
    1. Buxbaum JN, Linke RP. A molecular history of the amyloidoses. J Mol Biol. 2012;421:142–159. doi: 10.1016/j.jmb.2012.01.024. - DOI - PubMed
    1. David A, Hawkins PN, Polydefkis M. Oligonucleotide drugs for transthyretin amyloidosis. N Engl J Med. 2018;37:2085–2086. doi: 10.1056/NEJMc1810994. - DOI - PubMed
    1. Rapezzi C, Elliott P, Damy T, Nativi-Nicolau J, Berk JL, Velazquez EJ, et al. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy. JACC: Heart Failure. 2021;9:115–123. doi: 10.1016/j.jchf.2020.09.011. - DOI - PubMed
    1. Gillmore JD, Gane E, Taubel J, Kao J, Fontana M, Maitland ML, et al. CRISPR-Cas9 In Vivo gene editing for transthyretin amyloidosis. N Engl J Med. 2021;385:493–502. doi: 10.1056/NEJMoa2107454. - DOI - PubMed

LinkOut - more resources